Neon Therapeutics initiated with a Buy at Berenberg. Berenberg analyst Shanshan Xu initiated Neon Therapeutics with a Buy rating and $15 price target, stating that it has generated “compelling” data for NEO-PV-01. Early clinical data points to a clear efficacy signal, which he believes is not well understood by the Street, Xu tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.